Basic properties and molecular mechanisms of exogenous chemical carcinogens

Carcinogenesis

Volumn 31, Issue 2, 2010, Pages 135-148

  Irigaray, Philippe ^a   Belpomme, Dominique ^a,b  

^a Association for Research and Treatments Against Cancer ARTAC   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE; 4,4' ISOPROPYLIDENEDIPHENOL; ACROLEIN; ALKYLATING AGENT; ANTIESTROGEN; AROMATIC AMINE; ASBESTOS; BENZENE; CARCINOGEN; CYTOCHROME P450; DIOXIN; FORMALDEHYDE; HALOGENATED HYDROCARBON; METAL; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PESTICIDE; PHTHALIC ACID; POLYCYCLIC AROMATIC HYDROCARBON; VINYL CHLORIDE;

ADIPOSE TISSUE; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; DETOXIFICATION; DNA ADDUCT; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; EPIGENETICS; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LIPOPHILICITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; MUTAGENESIS; MUTAGENICITY; NONHUMAN; POLLUTANT; PRIORITY JOURNAL; REVIEW; SMOKING; CHEMICALLY INDUCED DISORDER; NEOPLASM;

CARCINOGENS; CARCINOGENS, ENVIRONMENTAL; HUMANS; NEOPLASMS;

EID: 77649220070     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp252     Document Type: Review

References (219)

1. Jackson, A.L. et al. (2001) The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res., 477, 7-21.
2. Belpomme, D. et al. (2007) The growing incidence of cancer: role of lifestyle and screening detection. Int. J. Oncol., 30, 1037-1049.
3. Irigaray, P. et al. (2007) Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed. Pharmacother., 61, 640-658.
4. Weinstein, I.B. (1988) The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment-twenty-seventh G.H.A. Clowes memorial award lecture. Cancer Res., 48, 4135-4143.
5. Loeb, L.A. et al. (2008) Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res., 68, 6863-6872.
6. Berenblum, I. et al. (1947) A new, quantitative, approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br. J. Cancer, 1, 383-391.
7. Boutwell, R.K. (1964) Some biological aspects of skin carcinogenesis. Prog. Exp. Tumor Res., 4, 207-250.
8. Foulds, L. (1954) The experimental study of tumor progression: a review. Cancer Res., 14, 327-339.
9. Weisburger, E.K. (1983) History of the bioassay program of the National Cancer Institute. Prog. Exp. Tumor Res., 26, 187-201.
10. Pitot, H.C. et al. (1991) Facts and theories concerning the mechanisms of carcinogenesis. FASEB J., 5, 2280-2286.
11. Potter, V.R. (1981) A new protocol and its rationale for the study of initiation and promotion of carcinogenesis in rat liver. Carcinogenesis, 2, 1375-1379.
12. Hennings, H. et al. (1985) Two-stage tumor promotion in mouse skin: an alternative interpretation. J. Natl Cancer Inst., 74, 735-740.
13. Hennings, H. et al. (1983) Malignant conversion of mouse skin tumours is increased by tumour initiators and unaffected by tumour promoters. Nature, 304, 67-69.
14. Trosko, J.E. et al. (2005) The emperor wears no clothes in the field of carcinogen risk assessment: ignored concepts in cancer risk assessment. Mutagenesis, 20, 81-92.
15. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
16. Weinstein, I.B. (1991) Mitogenesis is only one factor in carcinogenesis. Science, 251, 387-388.
17. O'Connell, J.F. et al. (1986) Enhanced malignant progression of mouse skin tumors by the free-radical generator benzoyl peroxide. Cancer Res., 46, 2863-2865.
18. Weinberg, R.A. (2007) The Biology of Cancer. Garland Science, Taylor & Francis Group, LLC, London, 864 pp.
19. Weinstein, I.B. et al. (1982) Mechanisms of multistage carcinogenesis and their relevance to tumor cell heterogeneity. In Owens, A.H., Coffey, D.S. and Baylin, S.B. (eds.) Tumor Cell Heterogeneity. Academic Press, New York, pp. 261-283.
20. Niedel, J.E. et al. (1983) Phorbol diester receptor copurifies with protein kinase C. Proc. Natl Acad. Sci. USA, 80, 36-40.
21. Parker, P.J. et al. (1986) The complete primary structure of protein kinase C-the major phorbol ester receptor. Science, 233, 853-859.
22. Umemura, T. et al. (1999) Pentachlorophenol (PCP) produces liver oxidative stress and promotes but does not initiate hepatocarcinogenesis in B6C3F1 mice. Carcinogenesis, 20, 1115-1120.
23. Weis, L.M. et al. (1998) Bay or baylike regions of polycyclic aromatic hydrocarbons were potent inhibitors of Gap junctional intercellular communication. Environ. Health Perspect., 106, 17-22.
24. Ghoshal, S. et al. (1999) Epigenetic toxicity of a mixture of polycyclic aromatic hydrocarbons on gap junctional intercellular communication before and after biodegradation. Environ. Sci. Technol., 33, 1044-1050.
25. Trosko, J.E. et al. (2005) The role of human adult stem cells and cell-cell communication in cancer chemoprevention and chemotherapy strategies. Mutat. Res., 591, 187-197.
26. Klaunig, J.E. et al. (1990) Biology of disease: role of inhibition of intercellular communication in carcinogenesis. Lab. Invest., 62, 135-146.
27. Michael, K. (2006) Nuclear factor-kB in cancer development and progression. Nature, 44, 431-435.
28. Durando, M. et al. (2007) Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environ. Health Perspect., 115, 80-86.
29. vom Saal, F.S. et al. (1997) Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc. Natl Acad. Sci. USA, 94, 2056-2061.
30. Birnbaum, L.S. (1995) Workshop on perinatal exposure to dioxin-like compounds. V. Immunologic effects. Environ. Health Perspect., 103, 157-160.
31. Repetto, R. et al. (1997) Pesticides and immunosuppression: the risks to public health. Health Policy Plan, 12, 97-106.
32. Hardell, L. et al. (2003) Is the decline of the increasing incidence of non-Hodgkin lymphoma in Sweden and other countries a result of cancer preventive measures? Environ. Health Perspect., 111, 1704-1706.
33. Denison, M.S. et al. (2003) Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol., 43, 309-334.
34. Nebert, D.W. et al. (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer, 6, 947-960.
35. Ames, B.N. et al. (1990) Too many rodent carcinogens: mitogenesis increases mutagenesis. Science, 249, 970-971.
36. Pitot, H.C. et al. (1987) A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their doseresponse relationships to altered hepatic foci. Carcinogenesis, 8, 1491-1499.
37. Sargent, L. et al. (1989) Ploidy and karyotype of hepatocytes isolated from enzyme-altered foci in two different protocols of multistage hepatocarcinogenesis in the rat. Carcinogenesis, 10, 387-391.
38. Meister, A. (1983) Selective modification of glutathione metabolism. Science, 220, 471-477.
39. Hodgson, E. et al. (2008) Metabolic interactions of agrochemicals in humans. Pest Manag. Sci., 64, 617-621.
40. Nebert, D.W. et al. (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem., 279, 23847-23850.
41. Yu, Z. et al. (1999) Human DNA repair systems: an overview. Environ. Mol. Mutagen., 33, 3-20.
42. Doll, R. et al. (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst., 66, 1191-1308.
43. IARC. (2004) IARC working group on the evolution of carcinogenic risks to humans: tobacco smoke and involuntary smoking. IARC Monogr. Eval. Carcinog. Risk Hum., 83.
44. Hecht, S.S. (1999) Tobacco smoke carcinogens and lung cancer. J. Natl Cancer Inst., 91, 1194-1210.
45. Severson, R.F. et al. (1976) Isolation, identification, and quantification of polynuclear aromatic hydrocarbons in tobacco smoke. In Freudenthal, R.I. and Jones, P.W. (eds.) Carcinogenesis-A Comprehensive Survey, Vol. 1, Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism, and Carcinogenesis. Raven Press, New York, pp. 253-270.
46. Rubin, H. (2002) Selective clonal expansion and microenvironmental permissiveness in tobacco carcinogenesis. Oncogene, 21, 7392-7411.
47. Vineis, P. et al. (1997) Aromatic amines and cancer. Cancer Causes Control, 8, 346-355.
48. Lutz, W.K. (1990) Dose-response relationship and low dose extrapolation in chemical carcinogenesis. Carcinogenesis, 11, 1243-1247.
49. Feng, B.Y. et al. (2006) Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J. Med. Chem., 49, 2151-2154.
50. Kurahashi, N. et al. (2008) Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int. J. Cancer, 122, 653-657.
51. Ferguson, L.R. (2002) Natural and human-made mutagens and carcinogens in the human diet. Toxicology, 181-182, 79-82.
52. Phillips, D.H. (1999) Polycyclic aromatic hydrocarbons in the diet. Mutat. Res., 443, 139-147.
53. Lijinsky, W. (1998) N-nitroso compounds in the diet. Mutat. Res., 443, 129-138.
54. Wild, C.P. et al. (2002) The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis, 17, 471-481.
55. Knize, G. et al. (1999) Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Adv. Exp. Med. Biol., 459, 179-193.
56. Sugimura, T. (1997) Overview of carcinogenic heterocyclic amines. Mutat. Res., 376, 211-219.
57. Felton, J.S. et al. (1991) Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food. Mutat. Res., 259, 205-217.
58. Belpomme, D. et al. (2007) The multitude and diversity of environmental carcinogens. Environ. Res., 105, 414-429.
59. Ward, J. (2007) The two-year rodent carcinogenesis bioassays. Will it survive? J. Toxicol. Pathol., 20, 13-19.
60. IARC. (1996) IARC working group on the evolution of carcinogenic risks to humans: some pharmaceutical drugs. IARC Monogr. Eval. Carcinog. Risks Hum., 66.
61. Belpomme, D. et al. (1974) Malignancies possibly secondary to anticancer therapy. In Mathe, G. and Oldham, R.K. (eds.) Recent Results in Cancer Research. Vol. 49, Springer-Verlag, New York, pp. 115-123.
62. Kumle, M. et al. (2002) Use of oral contraceptives and breast cancer risk: the Norwegiane Swedish women's lifestyle and health cohort study. Cancer Epidemiol. Biomarkers Prev., 11, 1375-1381.
63. Beral, V. (2003) Million women study collaborators: breast cancer and hormone replacement in the million women study. Lancet, 362, 419-427.
64. Huncharek, M. et al. (2005) Personal use of hair dyes and the risk of bladder cancer: results of a meta-analysis. Public Health Rep., 120, 31-38.
65. Rauscher, G.H. et al. (2004) Hair dye use and risk of adult acute leukemia. Am. J. Epidemiol., 160, 19-25.
66. Darbre, P.D. et al. (2008) Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J. Appl. Toxicol., 28, 561-578.
67. Mizuno, N. et al. (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev., 55, 425-461.
68. Jakoby, W.B. et al. (1990) The enzymes of detoxication. J. Biol. Chem., 265, 20715-20718.
69. Irigaray, P. et al. (2007) Overweight/obesity and cancer genesis: more than a biological link. Biomed. Pharmacother., 61, 665-678.
70. IARC. (2002) Weight Control and Physical Activity. IARC Handbooks of Cancer Prevention. Vol. 6, IARC Press, Lyon.
71. Irigaray, P. et al. (2005) Behaviour of dioxin in pig adipocytes. Food Chem. Toxicol., 43, 457-460.
72. Irigaray, P. et al. (2006) Benzo[a]pyrene impairs beta-adrenergic stimulation of adipose tissue lipolysis and causes weight gain in mice. A novel molecular mechanism of toxicity for a common food pollutant. FEBS J., 273, 1362-1372.
73. Irigaray, P. et al. (2009) Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons. Toxicol. Lett., 187, 35-39.
74. Ohmiya, Y. et al. (1977) Effect of starvation on excretion distribution and metabolism of DDT in mice. Tobuku J. Exp. Med., 122, 143-153.
75. Payne, J. et al. (2001) Mixtures of four organochlorines enhance human breast cancer cell proliferation. Environ. Health Perspect., 109, 391-397.
76. Mes, J. et al. (1974) Di-n-butyl-and di-2-ethylhexyl phthalate in human adipose tissue. Bull. Environ. Contam. Toxicol., 12, 721-725.
77. Mullerova, D. et al. (2007) White adipose tissue: storage and effector site for environmental pollutants. Physiol. Res., 56, 375-381.
78. Lawley, P.D. (1994) Historical origins of current concepts of carcinogenesis. Adv. Cancer Res., 65, 17-111.
79. Guengerich, F.P. (1992) Metabolic activation of carcinogens. Pharmacol. Ther., 54, 17-61.
80. Kohlmeier, L. et al. (1995) Dietary modifiers of carcinogenesis. Environ. Health Perspect., 103, 177-184.
81. Yang, S.K. et al. (1976) Enzymatic conversion of benzo(a)pyrene leading predominantly to the diol-epoxide r-7, t-8-dihydroxy-t-9, 10-oxy-7, 8, 9, 10-tetrahydrobenzo(a)pyrene through a single enantiomer of r-7, t-8-dihydroxy-7, 8-dihydrobenzo(a)pyrene. Proc. Natl Acad. Sci. USA, 73, 2594-2598.
82. Kim, J.H. et al. (1998) Metabolism of benzo[a]pyrene and benzo[a]pyrene-7, 8-diol by human cytochrome P450 1B1. Carcinogenesis, 19, 1847-1853.
83. Long, D.J. et al. (2000) NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res., 60, 5913-5915.
84. Hajos, A.K. et al. (1991) Purified NAD(P)H-quinone oxidoreductase enhances the mutagenicity of dinitropyrenes in vitro. J. Biochem. Toxicol., 6, 277-282.
85. Pullman, A. et al. (1955) Electronic structure and carcinogenic activity of aromatic molecules; new developments. Adv. Cancer Res., 3, 117-169.
86. Miller, J.A. et al. (1977) Ultimate chemical carcinogens as reactive mutagenic eletrophiles. In Hiatt, H.H., Watson, J.D. and Winsten, J.A. (eds.) Origins of Human Cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 605-627.
87. Willhite, C.C. (1982) Toxicology update: acrylonitrile. J. Appl. Toxicol., 2, 54-63.
88. Woutersen, R.A. (1998) Toxicologic profile of acrylonitrile. Scand. J. Work Environ. Health, 24, 5-9.
89. Sumner, S.C. et al. (1999) Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem. Res. Toxicol., 12, 1110-1116.
90. Guengerich, F.P. et al. (1981) In vitro metabolism of acrylonitrile to 2-cyanoethylene oxide, reaction with glutathione, and irreversible binding to proteins and nucleic acids. Cancer Res., 41, 4925-4933.
91. Oesch, R. et al. (1971) Hepatic epoxide hydrase. Structure-activity relationships for substrates and inhibitors. Biochemistry, 10, 4858-4864.
92. IARC. (1983) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans-Polynuclear Aromatic Compounds. Vol. 32, International Agency for Research into Cancer, Lyon, pp. 211-224.
93. Trush, M.A. et al. (1985) Oxidant-dependent metabolic activation of polycyclic aromatic hydrocarbons by phorbol ester-stimulated human polymorphonuclear leukocytes: possible link between inflammation and cancer. Proc. Natl Acad. Sci. USA, 82, 5194-5198.
94. Mallet, W.G. et al. (1991) Activation of (+2)-trans-7, 8-dihydroxy-7, 8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leukocytes or myeloperoxidase. Carcinogenesis, 12, 521-524.
95. Kadlubar, F.F. et al. (1992) Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect., 98, 69-74.
96. Fretland, A.J. et al. (2000) Epoxide hydrolases: biochemistry and molecular biology. Chem. Biol. Interact., 129, 41-59.
97. Guengerich, F.P. (2000) Metabolism of chemical carcinogens. Carcinogenesis, 21, 345-351.
98. Benson, A.M. et al. (1980) Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl Acad. Sci. USA, 77, 5216-5220.
99. Talalay, P. et al. (1995) Chemoprotection against cancer by phase 2 enzyme induction. Toxicol. Lett., 82/83, 173-179.
100. Zhang, Y. et al. (1994) Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl Acad. Sci. USA, 91, 3147-3150.
101. Guengerich, F.P. (1998) The environmental genome project: functional analysis of polymorphisms. Environ. Health Perspect., 106, 365-368.
102. Davidson, N.E. et al. (1990) Transcriptional control of glutathione Stransferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1, 2-dithiole-3-thione (oltipraz) in rat liver. Cancer Res., 50, 2251-2255.
103. Talalay, P. et al. (1988) Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl Acad. Sci. USA, 85, 8261-8265.
104. Prestera, T. et al. (1993) Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc. Natl Acad. Sci. USA, 90, 2965-2969.
105. Bartsch, H. et al. (1992) Endogenously formed N-nitroso compounds and nitrosating agents in human cancer etiology. Pharmacogenetics, 2, 272-277.
106. Tannenbaum, S.R. et al. (1980) Intestinal formation of nitrite and Nnitroso compounds. IARC Sci. Publ., 31, 2819.
107. Ashby, J. et al. (1993) The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures. Mutat. Res., 286, 3-74.
108. Tennant, R.W. (1993) A perspective on nonmutagenic mechanisms in carcinogenesis. Environ. Health Perspect., 101, 231-236.
109. Gu, Y.Z. et al. (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol., 40, 519-561.
110. Fernandez-Salguero, P.M. et al. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 268, 722-726.
111. Lahvis, G.P. et al. (2005) The aryl hydrocarbon receptor is required for developmental closure of the ductus venosus in the neonatal mouse. Mol. Pharmacol., 67, 714-720.
112. Fuji-Kuriyama, Y. et al. (2003) Transcriptional roles of AhR in expression of biological effects induced by endocrine disruptors. Pure Appl. Chem., 75, 1819-1826.
113. Silberhom, E.M. et al. (1990) Carcinogenicity of polyhalogenated biphenyls: PCBs and PBBs. Crit. Rev. Toxicol., 20, 440-496.
114. Nebert, D.W. (1990) Drug metabolism. Growth signal pathways. Nature, 347, 709-710.
115. Whitlock, J.P.Jr. (1999) Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol., 39, 103-125.
116. Perret, A. et al. (1998) Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. Biochemistry, 37, 11412-11424.
117. Schiestl, R.H. et al. (1997) Polychlorinated biphenyls and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin induce intrachromosomal recombination in vitro and in vivo. Cancer Res., 57, 4378-4383.
118. Stohs, S.J. (1990) Oxidative stress induced by 2.3.7.8-tetrachlorodibenzo-p-dioxin (TCDD). Free Radic. Biol. Med., 9, 79-90.
119. Puga, A. et al. (2000) Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J. Biol. Chem., 275, 2943-2950.
120. Currier, N. et al. (2005) Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol. Pathol., 33, 726-737.
121. Ohtake, F. et al. (2003) Modulation of oestrogen receptor signaling by association with the activated dioxin receptor. Nature, 423, 545-550.
122. Henry, E.C. et al. (2008) Molecular determinants of species-specific agonist and antagonist activity of a substituted flavone towards the aryl hydrocarbon receptor. Arch. Biochem. Biophys., 72, 77-88.
123. Poland, A. et al. (1994) Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol. Pharmacol., 46, 915-921.
124. Nebert, M.a, Q. et al. (2003) Origins of individual variability in P4501A induction. Chem. Res. Toxicol., 16, 249-260.
125. Bartkova, J. et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-870.
126. Hemminki, K. (1993) DNA adducts, mutations and cancer. Carcinogenesis, 14, 2007-2012.
127. Dipple, A. (1995) DNA adducts of chemical carcinogens. Carcinogenesis, 16, 437-441.
128. Sancar, A. (1994) Mechanisms of DNA excision repair. Science, 266, 1954-1956.
129. Modrich, P. et al. (1996) Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem., 65, 101-133.
130. Abbas, T. et al. (2009) p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer, 9, 400-414.
131. Yuspa, S.H. et al. (1988) Chemical carcinogenesis: from animal models to molecular models in one decade. Adv. Cancer Res., 50, 25-70.
132. Martelli, A. et al. (1988) Comparative study of DNA damage and repair induced by ten N-nitroso compounds in primary cultures of human and rat hepatocytes. Cancer Res., 48, 4144-4152.
133. Wiencke, J.K. et al. (1990) Molecular dosimetry of DNA adducts and sister chromatid exchanges in human lymphocytes treated with benzo[a]pyrene. Carcinogenesis, 11, 1497-1502.
134. Wilson, V.L. et al. (1989) Alkyl and aryl carcinogen adducts detected in human peripheral lung. Carcinogenesis, 10, 2149-2153.
135. van Schooten, F.J. et al. (1990) Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. Carcinogenesis, 11, 1677-1681.
136. Li, D. et al. (1996) Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res., 16, 287-293.
137. Pfohl-Leszkowicz, A. et al. (1995) High levels of DNA adducts in human colon are associated with colorectal cancer. Cancer Res., 55, 5611-5616.
138. Hamada, K. et al. (1994) Mucosa-specific DNA adducts in human small intestine: a comparison with the colon. Carcinogenesis, 15, 2677-2680.
139. Wang, M. et al. (1998) DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res., 58, 38-41.
140. Denissenko, M.F. et al. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
141. Greenblatt, M.S. et al. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
142. Barrett, J.C. (1993) Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ. Health Perspect., 100, 9-20.
143. Loechler, E.L. (1996) The role of adduct site-specific mutagenesis in understanding how carcinogen-DNA adducts cause mutations: perspective, prospects and problems. Carcinogenesis, 17, 895-902.
144. Lutz, W.K. (1979) In vivo covalent binding of organic chemicals to DNA as a quantitative indicator in the process of chemical carcinogenesis. Mutat. Res., 65, 289-356.
145. Hollstein, M. et al. (1991) p53 Mutations in human cancers. Science, 253, 49-53.
146. Ashby, J. et al. (1991) Detection of human carcinogens. Nature, 352, 185-186.
147. Cadenas, E. et al. (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med., 29, 222-230.
148. Esumi, H. et al. (1994) U.S.-Japan cooperative cancer research program: seminar on nitric oxide synthase and carcinogenesis. Cancer Res., 54, 297-301.
149. Carter, E.A. et al. (1994) Nitric oxide production is intensely and persistently increased in tissue by thermal injury. Biochem. J., 304, 201-204.
150. Kang, D. et al. (2007) Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol. Biomarkers Prev., 16, 1581-1586.
151. Mitrunen, K. et al. (2001) Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis, 22, 827-829.
152. Schafer, F.Q. et al. (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med., 30, 1191-1212.
153. Kohen, R. et al. (2002) Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol., 30, 620-650.
154. Klaunig, J.E. et al. (2004) The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 44, 239-267.
155. Hensley, K. et al. (2000) Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med., 28, 1456-1462.
156. Hu, Y. et al. (2002) Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. Toxicol. Lett., 133, 33-45.
157. Cerutti, P.A. (1985) Prooxidant states and tumor promotion. Science, 227, 375-381.
158. Kuchino, Y. et al. (1987) Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature, 327, 77-79.
159. Cerutti, P. et al. (1994) The role of the cellular antioxidant defense in oxidant carcinogenesis. Environ. Health Perspect., 102, 123-129.
160. Upham, B.L. et al. (1997) Hydrogen peroxide inhibits gap junctional intercellular communication in glutathione sufficient but not glutathione deficient cells. Carcinogenesis, 18, 37-42.
161. Dreher, D. et al. (1996) Role of oxygen free radicals in cancer development. Eur. J. Cancer, 32A, 30-38.
162. Federico, A. et al. (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer, 121, 2381-2386.
163. Yoshida, R. et al. (2000) Oxidative stress induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin: an application of oxidative stress markers to cancer risk assessment of dioxins. Ind. Health, 38, 5-14.
164. Hu, C. et al. (2008) Possible involvement of oxidative stress in trichloroethylene-induced genotoxicity in human HepG2 cells. Mutat. Res., 652, 88-94.
165. Pérez-Maldonado, I.N. et al. (2005) DDT-induced oxidative damage in human blood mononuclear cells. Environ. Res., 98, 177-184.
166. Black, A.T. et al. (2008) Increased oxidative stress and antioxidant expression in mouse keratinocytes following exposure to paraquat. Toxicol. Appl. Pharmacol., 231, 384-392.
167. Ruch, R.J. et al. (1988) Antioxidant prevention of tumor promoter induced inhibition of mouse hepatocyte intercellular communication. Cancer Lett., 33, 137-150.
168. Benz, C.C. et al. (2008) Ageing, oxidative stress and cancer: paradigms in parallax. Nat. Rev. Cancer, 8, 875-879.
169. Feinberg, A.P. et al. (2004) The history of cancer epigenetics. Nat. Rev. Cancer, 4, 143-153.
170. Bollati, V. et al. (2007) Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res., 67, 876-880.
171. IARC. (1980) Some metals and metallic compounds. IARC Monogr. Eval. Carcinog. Risk Hum., 23.
172. Cantor, K.P. et al. (2006) Water contaminants. Part 20. In Schottenfeld, D. and Fraumeni, F.Jr. (eds.) Cancer Epidemiology and Prevention, 3rd ed. Oxford University Press, New York.
173. Hayes, R.B. (1997) The carcinogenicity of metals in humans. Cancer Causes Control, 8, 371-385.
174. Gurpide, E. et al. (1984) Regulation of estrogen receptor levels in endometrial cancer cells. Prog. Clin. Biol. Res., 142, 145-165.
175. Witkiewicz-Kucharczyk, A. et al. (2006) Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis. Toxicol. Lett., 162, 29-42.
176. Snow, E.T. (1991) A possible role for chromium(III) in genotoxicity. Environ. Health Perspect., 92, 75-81.
177. Snow, E.T. (1994) Effects of chromium on DNA replication in vitro. Environ. Health Perspect., 102, 41-44.
178. Zhitkovich, A. et al. (1995) Glutathione and free amino acids form stable complexes with DNA following exposure of intact mammalian cells to chromate. Carcinogenesis, 16, 907-913.
179. Zhitkovich, A. et al. (1996) Formation of the amino acid-DNA complexes by hexavalent and trivalent chromium in vitro: importance of trivalent chromium and the phosphate group. Biochemistry, 35, 7275-7282.
180. Zwelling, L.A. et al. (1979) DNA-protein and DNA interstrand crosslinking by cisand trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res., 39, 365-369.
181. Donahue, B.A. et al. (1990) Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry, 29, 5872-5880.
182. Costa, M. (1991) Molecular mechanisms of nickel carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 31, 321-337.
183. Liu, J. et al. (2001) Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol. Sci., 61, 314-320.
184. Vega, L. et al. (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Pharmacol., 172, 225-232.
185. Zhao, C.Q. et al. (1997) Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl Acad. Sci. USA, 94, 10907-10912.
186. Gilmour, P.S. et al. (1997) Free radical activity of industrial fibers: role of iron in oxidative stress and activation of transcription factors. Environ. Health Perspect., 105, 1313-1317.
187. Mossman, B.T. et al. (2006) Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am. J. Respir. Cell Mol. Biol., 34, 666-669.
188. Peto, J. et al. (2001) Genetics and the common cancers. Eur. J. Cancer, 37, 88-96.
189. Shields, P.G. et al. (2000) Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J. Clin. Oncol., 18, 2309-2315.
190. Houlston, R.S. et al. (2004) The search for low-penetrance cancer susceptibility alleles. Oncogene, 23, 6471-6476.
191. Ponder, B.A.J. (2001) Cancer genetics. Nature, 411, 336-341.
192. Knudsen, L.E. et al. (2000) Risk assessment: the importance of genetic polymorphisms in man. Mutat. Res., 482, 83-88.
193. Harris, C.C. et al. (1976) Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. Science, 194, 1067-1069.
194. Berwick, M. et al. (2000) Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J. Natl Cancer Inst., 92, 874-897.
195. Nebert, D.W. et al. (2004) Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur. J. Pharmacol., 500, 267-280.
196. Johansson, I. et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA, 90, 11825-11829.
197. Sram, R.J. et al. (2000) Molecular epidemiology studies on occupational and environmental exposure to mutagens and carcinogens, 1997-1999. Environ. Health Perspect., 108, 57-70.
198. Conney, A.H. (1982) Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes Memorial Lecture. Cancer Res., 42, 4875-4917.
199. Spink, D.C. et al. (1998) Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis, 19, 291-298.
200. Spivack, S.D. et al. (2003) Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin. Cancer Res., 9, 6002-6011.
201. Kawajiri, K. (1999) CYP1A1. IARC Sci. Publ., 148, 159-172.
202. Shaw, G.L. et al. (1998) Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 7, 215-219.
203. Bartsch, H. et al. (2007) Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res., 174, 19-36.
204. Wu, X. et al. (1998) Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol. Biomarkers Prev., 7, 13-18.
205. Taioli, E. et al. (1999) Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect. Prev., 23, 232-237.
206. Saintot, M. et al. (2004) Interaction between genetic polymorphism of cytochrome P450-1B1 and environmental pollutants in breast cancer risk. Eur. J. Cancer Prev., 13, 83-86.
207. Rotunno, M. et al. (2009) Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS ONE, 4, e5652.
208. Van Schooten, F.J. et al. (2004) Myeloperoxidase (MPO)-463G/A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol. Biomarkers Prev., 13, 828-833.
209. Xu, L.L. et al. (2002) Counterpoint: the myeloperoxidase-463G/A polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol. Biomarkers Prev., 11, 1555-1559.
210. Cho, C.G. et al. (2006) Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk. J. Korean Med. Sci., 21, 1075-1079.
211. Cartwright, R.A. et al. (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2, 842-845.
212. Bell, D.A. et al. (1995) Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res., 55, 3537-3542.
213. Lang, N.P. et al. (1994) Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prev., 3, 675-682.
214. Mohrenweiser, H.W. et al. (2003) Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat. Res., 526, 93-125.
215. Spitz, M.R. et al. (2003) Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev., 12, 689-698.
216. Patel, A.V. et al. (2005) A prospective study of XRCC1 (X-ray crosscomplementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res., 7, R1168-R1173.
217. Whibley, C. et al. (2009) p53 Polymorphisms: cancer implications. Nat. Rev. Cancer, 9, 95-107.
218. Weston, A. et al. (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ. Health Perspect., 105 (suppl. 4), 919-926.
219. Schaid, D.J. et al. (1999) Discovery of cancer susceptibility genes: study designs, analytic approaches, and trends in technology. JNCI Monogr., 26, 1-16.